2016 American Transplant Congress
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.
Columbia University Medical Center, NYC.
Intro: CAAMR is an increasingly recognized cause of renal allograft failure with limited treatment options. Many patients with CAAMR have engagement of both T and…2016 American Transplant Congress
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.
Backgroud: The best choice to treat AMR is not supported by several evidences, and recently the interest in drugs as Bortezomib has improved. Aim: Evaluted…2016 American Transplant Congress
Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients.
Houston Methodist Hospital, Houston, TX.
Recent literature indicates an elevated rate of de novo DSA (dnDSA) following BK viremia (BKV) in renal transplant recipients (RTR). We sought to review our…2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
Mean fluorescence intensity (MFI) values obtained from Luminex-based single antigen bead (SAB) assays is a semi-quantitative result used to determine the relative strength of HLA…2016 American Transplant Congress
C1q Assays Are Not Associated with Clinical or Serologic Endpoints.
PURPOSE: The c1q assay has been proposed as a potential adjunct to standard donor specific antibody (DSA) testing designed to improve the specificity to identify…2016 American Transplant Congress
Identification of Donor HLA-Specific Antibodies as a Risk Factor for Graft Dysfunction and Failure Following BK Virus Associated Nephropathy.
Transplantation Medicine, Weill Cornell Medicine, New York, NY.
Background: BK virus associated nephropathy (BKVN) has emerged as a significant cause of graft dysfunction and graft failure. Identification of risk factors for graft dysfunction…2016 American Transplant Congress
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Extending the functionality of renal allografts is an essential goal of transplant medicine. HS patients (pts) are at increased risk for chronic ABMR (CABMR) due…2016 American Transplant Congress
Live Donor Kidney Transplantation of the Most Highly Sensitized Patients in the Era of Kidney Paired Donation.
Background: Despite effective kidney paired donation (KPD) programs, the most highly sensitized patients (calculated panel reactive antibody (cPRA) > 98%) remain significantly disadvantaged and accumulate…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 47
- Next Page »